Increased risk of recurrent thrombosis in patients with essential thrombocythemia carrying the homozygous JAK2 V617F mutation

Abstract Evidence suggests that the JAK2 V617F mutationis associated with an increased risk of first thrombosisin patients with essential thrombocythemia (ET). Whetherthis mutation is also a risk factor for recurrent thrombosis iscurrently unknown. To investigate the impact of the JAK2V617F mutation on the risk of recurrent thrombosis inpatients with ET, we carried out a multicentre retrospectivecohort study. We recruited 143 patients with previousarterial (64.4%) or venous major thrombosis (34.8%) orboth (0.8%); 98 of them (68.5%) carried the mutation